AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2092025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 2092025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (smokers)
Number of subjects: 76
Study 2092025 — intervention group
Group type: COMPARATOR
Intervention: Placebo (smokers)
Number of subjects: 76
Study 733569 — intervention group
Group type: EXPERIMENTAL
Intervention: VM 26 (podophyllin derivative) administered alone
Number of subjects: 21
Study 733569 — intervention group
Group type: COMPARATOR
Intervention: Control group (no VM 26)
Number of subjects: 21
Study 31116908 — intervention group
Group type: EXPERIMENTAL
Intervention: ProGlide (PG)
Number of subjects: 746
Study 31116908 — intervention group
Group type: COMPARATOR
Intervention: Prostar XL (PS)
Number of subjects: 746
Study 28704534 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention including dietary intervention with hypocaloric diet and assisted personalized physical aerobic and anaerobic activities for 3 weeks
Number of subjects: 14
Study 28704534 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 14
Study 26202594 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab plus placebo plus weekly paclitaxel (OP)
Number of subjects: 185
Study 26202594 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab plus bevacizumab plus paclitaxel (OBP)
Number of subjects: 185
Study 26202594 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus bevacizumab plus paclitaxel (BP)
Number of subjects: 185
Study 26202594 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab arms (OBP, OP)
Number of subjects: 185
Study 23643176 — intervention group
Group type: EXPERIMENTAL
Intervention: Uracil/tegafur (UFT) and cisplatin (400 mg/m² UFT on days 1-14 and 29-42, 80 mg/m² cisplatin on days 8 and 36)
Number of subjects: 70
Study 23643176 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine and cisplatin (20 mg/m² vinorelbine on days 1, 8, 29, and 36, 80 mg/m² cisplatin on days 1 and 29)
Number of subjects: 70
Study 21320300 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactor intervention including motivational aspects related to adherence (beliefs and behaviour), cognitive aspects (information about illness), skills (inhaled technique training), and reinforcement of cognitive-emotional aspects during four visits over one year.
Number of subjects: 140
Study 21320300 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified in the abstract).
Number of subjects: 140
Study 19377380 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan-based heparin bonded preconnected circuits (Vision HFOGBS, Gish, California, USA) with low-systemic heparin (125 IU/kg, ACT >250 s)
Number of subjects: 100
Study 19377380 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan-based heparin bonded preconnected circuits (Vision HFOGBS, Gish, California, USA) with full dose heparin
Number of subjects: 100
Study 19377380 — intervention group
Group type: COMPARATOR
Intervention: Uncoated controls (Vision HFO, Gish, USA)
Number of subjects: 100
Study 17297382 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose sulfate (CS) gel
Number of subjects: 36
Study 17297382 — intervention group
Group type: COMPARATOR
Intervention: KY Jelly
Number of subjects: 36
Study 15567011 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (25 mg/kg over 3 days) + sulfadoxine‐pyrimethamine (25 mg/kg sulfadoxine, 1.25 mg/kg pyrimethamine, single dose)
Number of subjects: 418
Study 15567011 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (25 mg/kg over 3 days) + sulfadoxine‐pyrimethamine
Number of subjects: 418
Study 15567011 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine + artesunate (4 mg/kg daily for 3 days)
Number of subjects: 418
Study 15567011 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine+sulfadoxine‐pyrimethamine
Number of subjects: 418
Study 15567011 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 418
Study 11683188 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 micromol/kg/d manganese supplementation (group 1, n = 121)
Number of subjects: 244
Study 11683188 — intervention group
Group type: COMPARATOR
Intervention: 0.0182 micromol/kg/d manganese supplementation (group 2, n = 123)
Number of subjects: 244
Study 11683188 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 micromol/kg/d manganese supplementation (group 1, n = 78)
Number of subjects: 244
Study 11683188 — intervention group
Group type: COMPARATOR
Intervention: 0.0182 micromol/kg/d manganese supplementation (group 2, n = 82)
Number of subjects: 244
Study 9653434 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapies for prevention and treatment of MAS
Number of subjects: 0
Study 8778001 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms pramlintide
Number of subjects: 84
Study 8778001 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms pramlintide
Number of subjects: 84
Study 8778001 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms pramlintide
Number of subjects: 84
Study 8778001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 2273080 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine 1 mg every night
Number of subjects: 102
Study 2273080 — intervention group
Group type: COMPARATOR
Intervention: Prazosin 1 mg three times a day
Number of subjects: 102
Study 6269789 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg ranitidine intravenously
Number of subjects: 8
Study 6269789 — intervention group
Group type: COMPARATOR
Intervention: 300 mg cimetidine intravenously
Number of subjects: 8
Study 31644381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based intervention
Number of subjects: 22
Study 31644381 — intervention group
Group type: COMPARATOR
Intervention: Tabletop intervention
Number of subjects: 22
Study 27190329 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (NAM)
Number of subjects: 100
Study 27190329 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer (SEV)
Number of subjects: 100
Study 25553511 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray during luteal phase
Number of subjects: 140
Study 23514626 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB (calcium salt, 1.5 g twice daily, total 3 g/day)
Number of subjects: 24
Study 23514626 — intervention group
Group type: COMPARATOR
Intervention: Control (inactive placebo powder)
Number of subjects: 24
Study 23514626 — intervention group
Group type: COMPARATOR
Intervention: HMB vs Control
Number of subjects: 24
Study 23514626 — intervention group
Group type: COMPARATOR
Intervention: HMB vs Control (female subjects)
Number of subjects: 24
Study 21544683 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote intermittent ischemia (RI) - three 5‐min cycles of left upper limb ischemia by cuff inflation
Number of subjects: 54
Study 21544683 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Plac) - without cuff inflation
Number of subjects: 54
Study 19523738 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide whitening strips (Crest Whitestrips)
Number of subjects: 40
Study 19523738 — intervention group
Group type: COMPARATOR
Intervention: Placebo strips without peroxide
Number of subjects: 40
Study 17530471 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg daily titrated every 3 months for 18 months)
Number of subjects: 55
Study 17530471 — intervention group
Group type: COMPARATOR
Intervention: Control (without lovastatin)
Number of subjects: 55
Study 15476153 — intervention group
Group type: EXPERIMENTAL
Intervention: Renzapride 4 mg
Number of subjects: 48
Study 15476153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15476153 — intervention group
Group type: EXPERIMENTAL
Intervention: Renzapride (1, 2, or 4 mg)
Number of subjects: 48
Study 11404610 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic, supersaturated humidification through a nasal cannula (Vapotherm Inc.)
Number of subjects: 0
Study 11404610 — intervention group
Group type: COMPARATOR
Intervention: Standard bedside humidifier
Number of subjects: 0
Study 8816337 — intervention group
Group type: COMPARATOR
Intervention: Stage II impingement syndrome (group 2)
Number of subjects: 47
Study 8816337 — intervention group
Group type: COMPARATOR
Intervention: Rotator cuff tears or stage III impingement (group 3)
Number of subjects: 47
Study 8816337 — intervention group
Group type: COMPARATOR
Intervention: Normal shoulders (group 1)
Number of subjects: 47
Study 8816337 — intervention group
Group type: COMPARATOR
Intervention: Stage II impingement syndrome (group 2) and Rotator cuff tears (group 3)
Number of subjects: 47
Study 1428303 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-carnitine
Number of subjects: 100
Study 1428303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 6145832 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hormone therapies using tamoxifen, aminoglutethimide with hydrocortisone, and danazol (TAD)
Number of subjects: 222
Study 6145832 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 222
Study 6145832 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen and/or subsequent endocrine therapy
Number of subjects: 222
Study 6145832 — intervention group
Group type: EXPERIMENTAL
Intervention: TAD
Number of subjects: 222
Study 6145832 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 222
Study 6145832 — intervention group
Group type: EXPERIMENTAL
Intervention: TAD and Tamoxifen
Number of subjects: 222
Study 31211607 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy (weekly session for 1 month, total of four sessions)
Number of subjects: 40
Study 31211607 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (initial session guided by acupuncturist, 2 month take home supply of acupressure patches, reviewed fortnightly)
Number of subjects: 40
Study 28969439 — intervention group
Group type: EXPERIMENTAL
Intervention: CCBT (computer-assisted cognitive-behavioral therapy) using the 'Good Days Ahead' program
Number of subjects: 154
Study 28969439 — intervention group
Group type: COMPARATOR
Intervention: Standard CBT (cognitive-behavioral therapy)
Number of subjects: 154
Study 26481083 — intervention group
Group type: COMPARATOR
Intervention: rosuvastatin 10 mg/d
Number of subjects: 12705
Study 26481083 — intervention group
Group type: COMPARATOR
Intervention: candesartan/hydrochlorothiazide 16/12.5 mg/d
Number of subjects: 12705
Study 26481083 — intervention group
Group type: COMPARATOR
Intervention: Combination of rosuvastatin and candesartan/hydrochlorothiazide
Number of subjects: 12705
Study 26481083 — intervention group
Group type: COMPARATOR
Intervention: Placebo for rosuvastatin
Number of subjects: 12705
Study 26481083 — intervention group
Group type: COMPARATOR
Intervention: Placebo for candesartan/hydrochlorothiazide
Number of subjects: 12705
Study 24586490 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib 40 mg
Number of subjects: 102
Study 24586490 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib 80 mg
Number of subjects: 102
Study 24586490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 22257580 — intervention group
Group type: EXPERIMENTAL
Intervention: glimepiride/SR metformin 2 mg/500 mg
Number of subjects: 12
Study 20961974 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional training intervention
Number of subjects: 64
Study 20961974 — intervention group
Group type: COMPARATOR
Intervention: Control training
Number of subjects: 64
Study 17586384 — intervention group
Group type: EXPERIMENTAL
Intervention: Square-edged PMMA IOL
Number of subjects: 118
Study 17586384 — intervention group
Group type: COMPARATOR
Intervention: Round-edged PMMA IOL
Number of subjects: 118
Study 16457090 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish version of the Fatigue Impact Scale (FIS)
Number of subjects: 355
Study 12400767 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP of 10 cm H2O
Number of subjects: 84
Study 12400767 — intervention group
Group type: COMPARATOR
Intervention: PEEP of 5 cm H2O
Number of subjects: 84
Study 9972769 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium infusion to achieve a steady-state 50% block at the hand (n = 10)
Number of subjects: 20
Study 9972769 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium infusion to achieve a steady-state 75% block at the hand (n = 10)
Number of subjects: 20
Study 9972769 — intervention group
Group type: COMPARATOR
Intervention: Comparison of cuff pressure measurement and video imaging (VI)
Number of subjects: 20
Study 7587258 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% potassium hydroxide preparations of tracheo-bronchial aspirates
Number of subjects: 22
Study 7587258 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 22
Study 1683332 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotepine
Number of subjects: 40
Study 1683332 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 40
Study 7041523 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 42
Study 7041523 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 42
Study 31937586 — intervention group
Group type: EXPERIMENTAL
Intervention: Rovatirelin 1.6 mg
Number of subjects: 652
Study 31937586 — intervention group
Group type: EXPERIMENTAL
Intervention: Rovatirelin 2.4 mg
Number of subjects: 652
Study 31937586 — intervention group
Group type: EXPERIMENTAL
Intervention: Rovatirelin 2.4 mg (pooled analysis)
Number of subjects: 652
Study 31937586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study 30893638 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA) 600 mg/kg diet/day
Number of subjects: 16
Study 30893638 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA) 1200 mg/kg diet/day
Number of subjects: 16
Study 30893638 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA) 1800 mg/kg diet/day
Number of subjects: 16
Study 30893638 — intervention group
Group type: COMPARATOR
Intervention: Guanidinoacetic acid (GAA) 0 mg/kg diet/day (Control)
Number of subjects: 16
Study 29169546 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth electronic monitoring after arterial revascularization
Number of subjects: 0
Study 29169546 — intervention group
Group type: COMPARATOR
Intervention: Standard postdischarge care (implied control)
Number of subjects: 0
Study 27797985 — intervention group
Group type: EXPERIMENTAL
Intervention: Optometrist-led follow-up monitoring reviews
Number of subjects: 0
Study 27797985 — intervention group
Group type: COMPARATOR
Intervention: Ophthalmologist-led follow-up monitoring reviews
Number of subjects: 0
Study 24293455 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg daily
Number of subjects: 281
Study 24293455 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 5 mg daily
Number of subjects: 281
Study 24293455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 22914079 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 30 mg bid from 24 to 96 hours after injury
Number of subjects: 62
Study 22914079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 18608540 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride-fortified bread (22 mmol/day potassium chloride)
Number of subjects: 6
Study 18608540 — intervention group
Group type: EXPERIMENTAL
Intervention: Breads with 30% sodium replaced by potassium salts
Number of subjects: 6
Study 18608540 — intervention group
Group type: EXPERIMENTAL
Intervention: Breads with 10% wheat flour replaced with soy flour
Number of subjects: 6
Study 18608540 — intervention group
Group type: COMPARATOR
Intervention: Standard bread
Number of subjects: 6
Study 17464718 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg day(-1)) for 7 days
Number of subjects: 40
Study 17464718 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 15163892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 0
Study 15163892 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0
Study 15163892 — intervention group
Group type: COMPARATOR
Intervention: Cessation of both therapies
Number of subjects: 0
Study 11683695 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg simplified lansoprazole suspension (nasogastrically)
Number of subjects: 36
Study 11683695 — intervention group
Group type: COMPARATOR
Intervention: 40 mg intravenous pantoprazole
Number of subjects: 36
Study 9712471 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplements containing Ephedra sinica (ma huang)
Number of subjects: 10
Study 9712471 — intervention group
Group type: COMPARATOR
Intervention: 25‐mg ephedrine capsule
Number of subjects: 10
Study 8308569 — intervention group
Group type: EXPERIMENTAL
Intervention: Rooming-in-hospital where formula supplementation was not allowed
Number of subjects: 165
Study 8308569 — intervention group
Group type: COMPARATOR
Intervention: Nursery
Number of subjects: 165
Study 8308569 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 165
Study 3167527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral neomycin and erythromycin base (Group A)
Number of subjects: 194
Study 3167527 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic metronidazole and gentamicin (Group B)
Number of subjects: 194
Study 3167527 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral and systemic antibiotics (Group C)
Number of subjects: 194
Study 3167527 — intervention group
Group type: COMPARATOR
Intervention: Oral antibiotics alone (Group A)
Number of subjects: 194
Study 31788791 — intervention group
Group type: COMPARATOR
Intervention: Fast propofol infusion
Number of subjects: 16
Study 31788791 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow propofol infusion
Number of subjects: 16
Study 30266593 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume-based TLC diet
Number of subjects: 31
Study 30266593 — intervention group
Group type: COMPARATOR
Intervention: Legume-free TLC diet
Number of subjects: 31
Study 28318353 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with symptomatic heart failure
Number of subjects: 314
Study 28318353 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with symptomatic heart failure
Number of subjects: 314
Study 28318353 — intervention group
Group type: COMPARATOR
Intervention: Comparison of men to women
Number of subjects: 314
Study 26124035 — intervention group
Group type: EXPERIMENTAL
Intervention: Angle Class II Division 2 malocclusion group
Number of subjects: 76
Study 26124035 — intervention group
Group type: COMPARATOR
Intervention: Control group (270 orthodontic patients: 168 female, 102 male)
Number of subjects: 76
Study 26124035 — intervention group
Group type: COMPARATOR
Intervention: Control group (270 orthodontic patients)
Number of subjects: 76
Study 22480831 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy
Number of subjects: 211
Study 22480831 — intervention group
Group type: COMPARATOR
Intervention: Emergency portacaval shunt
Number of subjects: 211
Study 22480831 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-Turcotte score
Number of subjects: 211
Study 22480831 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD
Number of subjects: 211
Study 20043136 — intervention group
Group type: EXPERIMENTAL
Intervention: DBDS-MPH (40 mg)
Number of subjects: 21
Study 20043136 — intervention group
Group type: COMPARATOR
Intervention: OROS-MPH (36 mg)
Number of subjects: 21
Study 17652642 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline 3 mg/24 hours
Number of subjects: 128
Study 17652642 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline 6 mg/24 hours
Number of subjects: 128
Study 17652642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 16254085 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical attractiveness of female faces
Number of subjects: 0
Study 16254085 — intervention group
Group type: COMPARATOR
Intervention: Physical attractiveness of male faces
Number of subjects: 0
Study 16254085 — intervention group
Group type: EXPERIMENTAL
Intervention: Attractive female faces
Number of subjects: 0
Study 12152371 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia femoral head and alumina acetabular liner
Number of subjects: 10
Study 12152371 — intervention group
Group type: COMPARATOR
Intervention: Alumina femoral head and alumina acetabular liner
Number of subjects: 10
Study 10201665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 18
Study 10201665 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 18
Study 8529142 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Managed Instruction (CMI) and keypad questions
Number of subjects: 0
Study 8529142 — intervention group
Group type: COMPARATOR
Intervention: Traditional Classroom Lecture (TCL)
Number of subjects: 0
Study 2141512 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (vincristine during irradiation and maintenance CCNU and vincristine, given in 6-weekly cycles for 1 year)
Number of subjects: 286
Study 2141512 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 286
Study 2141512 — intervention group
Group type: COMPARATOR
Intervention: Control group (craniospinal irradiation only)
Number of subjects: 286
Study 41151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear Magnetic Resonance (NMR) imaging
Number of subjects: 47
Study 30847706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling brace
Number of subjects: 45
Study 30847706 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 28340011 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb exercises (group 1)
Number of subjects: 198
Study 28340011 — intervention group
Group type: COMPARATOR
Intervention: Lower limb exercises (group 2)
Number of subjects: 198
Study 28340011 — intervention group
Group type: COMPARATOR
Intervention: No intervention (group 0)
Number of subjects: 198
Study 27681888 — intervention group
Group type: EXPERIMENTAL
Intervention: DAA-I 0.08 mg/kg
Number of subjects: 18
Study 27681888 — intervention group
Group type: EXPERIMENTAL
Intervention: DAA-I 0.70 mg/kg
Number of subjects: 18
Study 27681888 — intervention group
Group type: EXPERIMENTAL
Intervention: DAA-I 1.50 mg/kg
Number of subjects: 18
Study 27681888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18